The Latest Breaking News from Novo Nordisk

Semaglutide and liraglutide are sold under the brand names Wegovy, Ozempic, Rybelsus and Saxenda and are manufactured by Novo Nordisk

Researchers said instances were ‘rare’ but hundreds of thousands of people could still be affected due to the drugs’ popularity globally.

The drugs, although not officially approved for use in weight loss, have been touted as a “miracle” treatments for obesity.

Barclays strategists expect "disruption into a number of industries," thanks to drugs like Novo Nordisk's Ozempic and Wegovy.

Hailed as potential ‘game changer’ in tackling obesity, Semaglutide can also help those with type 2 diabetes

Researchers said semaglutide’s effectiveness in treating type 2 diabetes has been shown in some trials, but long-term data is ‘lacking’.

The study represents the first long-term, large-scale, real-world trial of the blockbuster drug, researchers said.

Danish pharmaceutical company Novo Nordisk has signed a deal with South Africa’s Aspen Pharmacare to produce human insulin specifically for diabetes patients in Africa where there is a dire need for the life-saving treatment

These three biotech stocks have massive growth opportunities on the horizon, and could add a huge boost to any portfolio. They play in some of the most in demand markets on the planet, and have track records of finding ways to introduce products into those markets to capture big profits.…

Novo Nordisk, the maker of the blockbuster obesity injection, has singlehandedly saved the country from recession

Ozempic has not shown increased risk of suicidal ideation in trials, but some users say it harmed their mental health.